西黄胶囊联合白蛋白紫杉醇治疗晚期三阴性乳腺癌临床研究

目的 探讨西黄胶囊联合白蛋白紫杉醇治疗晚期三阴性乳腺癌的临床疗效。方法 选择于本院就诊的80例晚期三阴性乳腺癌患者作为研究对象。所有患者随机分为对照组和治疗组，每组40例。对照组iv给予白蛋白紫杉醇，21 d为1个疗程，治疗3个疗程；治疗组在对照组治疗方案的基础上给予6粒/次的西黄胶囊，每日2次，21 d为一个疗程，治疗3个疗程。对比分析两组患者治疗后的临床效果；评估两组的卡氏（KPS）和视觉模拟评分（VAS）分值，并评价两组患者的肿瘤标志物水平，以及服药后不良反应的发生率。结果 两组患者治疗后，客观缓解率（ORR）对照组为60.0%，治疗组为75.0%；疾病控制率（CBR）对照组为77.5%，治疗组为87.5%，两组差异显著（P<0.05）。两组治疗后，KPS评分明显升高，VAS评分明显下降；治疗后治疗组的KPS评分和VAS评分明显优于对照组（P<0.05）。治疗后，两组肿瘤标记物CA-153、CEA水平较治疗前均显著降低（P<0.05），且治疗组明显低于对照组（P<0.05）。治疗组不良反应发生率与对照组比较显著降低（P<0.05）。结论 晚期三阴性乳腺癌患者给予西黄胶囊和白蛋白紫杉醇联合治疗，具有较高的临床疗效，且安全性较高。

Clinical study of Xihuang Capsule combined with albumin paclitaxel in treatment of advanced triple negative breast cancer

Objective To investigate the clinical effect of Xihuang Capsule combined with albumin paclitaxel in the treatment of advanced triple negative breast cancer. Methods A total of 80 patients with advanced triple negative breast cancer admitted to Cangzhou Central Hospital were selected as the study subjects. All patients were randomly divided into the control group and the treatment group, with 40 patients in each group. Patients in the control group were given albumin paclitaxel for a cycle of 21 d, and received continuous treatment for at least three cycles. The difference between the treatment group was given six capules of Xihuang Capsules twice a day for one course of treatment for 21 d based on the treatment of control group. The clinical effects of the two groups were compared and analyzed. The KPS and VAS scores of the two groups of patients were evaluated, and the tumor markers and the incidence of adverse reactions after taking the drug were recorded for statistical analysis. Results After treatment, the objective remission rate (ORR) was 60.0% in the control group and 75.0% in the treatment group. The disease control rate (CBR) was 77.5% in the control group and 85.7% in the treatment group. The difference between the two groups was statistically significant (P<0.05). After treatment, KPS score and VAS score in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, CA-153 and CEA levels of tumor markers in both groups were significantly lower than those before treatment (P<0.05), while CA-153 and CEA levels in the treatment group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Xihuang Capsule combined with albumin paclitaxel has higher clinical efficacy and safety in patients with advanced triple negative breast cancer.